February 20, 2013—Providers that have decided to use 340B-discounted drugs for their Medicaid patients need to have a mechanism in place to let state Medicaid officials know whenever they are unable to purchase a drug at its 340B price, the Health Resources and Services Administration (HRSA) says in a recent guidance document.
The new notification requirement, announced earlier this month, enables states to seek Medicaid drug rebates that they are entitled to but otherwise would not know were available.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)